Crosstalk between Tryptophan Metabolism and Cardiovascular Disease, Mechanisms, and Therapeutic Implications

Oxidative Medicine and Cellular Longevity

Volumn 2017, Issue , 2017, Pages

  Liu, Gang ^a   Chen, Shuai ^a   Zhong, Jin ^b,c   Teng, Kunling ^b   Yin, Yulong ^a,d,e  

^a INSTITUTE OF GEOLOGY AND GEOPHYSICS   (China)

^b INSTITUTE OF MICROBIOLOGY   (China)

^c UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^d HUNAN NORMAL UNIVERSITY   (China)

^e SOUTH CHINA AGRICULTURAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACIDS; CARDIOLOGY; METABOLISM; PHYSIOLOGY;

CARDIO-VASCULAR DISEASE; CORONARY HEART DISEASE; IMMUNE RESPONSE; INDOLEAMINE 2 ,3-DIOXYGENASE; INFLAMMATORY DISEASE; KYNURENINE PATHWAYS; MEDIATING AGENTS; PATHOPHYSIOLOGICAL;

DISEASES;

INDOLEAMINE 2,3 DIOXYGENASE; KYNURENINE; TRYPTOPHAN; TRYPTOPHAN 2,3 DIOXYGENASE;

AMINO ACID SYNTHESIS; ATHEROSCLEROSIS; BIOTRANSFORMATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DEGRADATION; HUMAN; IMMUNE RESPONSE; LIVER CELL; NONHUMAN; OXIDATIVE STRESS; REGULATORY T LYMPHOCYTE; REVIEW; TRYPTOPHAN METABOLISM; CARDIOVASCULAR DISEASES; CHEMISTRY; ENZYMOLOGY; INFLAMMATION; LIVER; METABOLISM; PATHOPHYSIOLOGY; SIGNAL TRANSDUCTION;

CELLS; DISEASES; METABOLISM; PATHOLOGY;

CARDIOVASCULAR DISEASES; HUMANS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; INFLAMMATION; KYNURENINE; LIVER; SIGNAL TRANSDUCTION; TRYPTOPHAN;

EID: 85015980902     PISSN: 19420900     EISSN: 19420994     Source Type: Journal    
DOI: 10.1155/2017/1602074     Document Type: Review

References (46)

1. G. F. Oxenkrug, "Genetic and hormonal regulation of tryptophan-kynurenine metabolism: implications for vascular cognitive impairment, major depressive disorder, and aging, " Annals of the New York Academy of Sciences, vol. 1122, pp. 35-49, 2007.
2. D. A. Chistiakov, A. N. Orekhov, and Y. V. Bobryshevy, "Cardiac extracellular vesicles in normal and infarcted heart, " International Journal of Molecular Sciences, vol. 17, no. 1, article 63, 2016.
3. L. Vécsei, L. Szalárdy, F. Fülöp, and J. Toldi, "Kynurenines in the CNS: recent advances and new questions, " Nature Reviews Drug Discovery, vol. 12, no. 1, pp. 64-82, 2013.
4. M. Nichols, N. Townsend, P. Scarborough, andM. Rayner, "Cardiovascular disease in Europe 2014: epidemiological update, " European Heart Journal, vol. 35, no. 42, pp. 2950-2959, 2014.
5. J. E. Cole, N. Astola, A. P. Cribbs et al., "Indoleamine 2, 3-dioxygenase-1 is protective in atherosclerosis and its metabolites provide new opportunities for drug development, " Proceedings of the National Academy of Sciences of the United States of America, vol. 112, no. 42, pp. 13033-13038, 2015.
6. A. N. Orekhov, "Mechanisms of atherogenesis and development of anti-atherosclerotic therapy, " Current Pharmaceutical Design, vol. 21, no. 9, pp. 1103-1106, 2015.
7. I. Tabas, K. J. Williams, and J. Borén, "Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications, " Circulation, vol. 116, no. 16, pp. 1832-1844, 2007.
8. N. J. C. King and S. R. Thomas, "Molecules in focus: indoleamine 2, 3-dioxygenase, " International Journal of Biochemistry and Cell Biology, vol. 39, no. 12, pp. 2167-2172, 2007.
9. O. Takikawa, "Biochemical and medical aspects of the indoleamine 2, 3-dioxygenase-initiated L-tryptophan metabolism, " Biochemical and Biophysical Research Communications, vol. 338, no. 1, pp. 12-19, 2005.
10. G. Werner-Felmayer, E. R. Werner, D. Fuchs, A. Hausen, G. Reibnegger, and H. Wachter, "Neopterin formation and tryptophan degradation by a human myelomonocytic cell line (THP-1) upon cytokine treatment, " Cancer Research, vol. 50, no. 10, pp. 2863-2867, 1990.
11. H. A. Walsh and N. P. Botting, "Purification and biochemical characterization of some of the properties of recombinant human kynureninase, " European Journal of Biochemistry, vol. 269, no. 8, pp. 2069-2074, 2002.
12. R. Schwarcz and R. Pellicciari, "Manipulation of brain kynurenines: glial targets, neuronal effects, and clinical opportunities, " Journal of Pharmacology and Experimental Therapeutics, vol. 303, no. 1, pp. 1-10, 2002.
13. T. W. Stone and L. G. Darlington, "Endogenous kynurenines as targets for drug discovery and development, " Nature Reviews Drug Discovery, vol. 1, no. 8, pp. 609-620, 2002.
14. A. Chiarugi, M. Calvani, E. Meli, E. Traggiai, and F. Moroni, "Synthesis and release of neurotoxic kynurenine metabolites by human monocyte-derived macrophages, " Journal of Neuroimmunology, vol. 120, no. 1-2, pp. 190-198, 2001.
15. T. J. Connor, N. Starr, J. B. O'Sullivan, and A. Harkin, "Induction of indolamine 2, 3-dioxygenase and kynurenine 3-monooxygenase in rat brain following a systemic inflammatory challenge: A role for IFN-" Neuroscience Letters, vol. 441, no. 1, pp. 29-34, 2008.
16. R. Schwarcz, "The kynurenine pathway of tryptophan degradation as a drug target, " Current Opinion in Pharmacology, vol. 4, no. 1, pp. 12-17, 2004.
17. T. W. Stone and M. N. Perkins, "Quinolinic acid: A potent endogenous excitant at amino acid receptors in CNS, " European Journal of Pharmacology, vol. 72, no. 4, pp. 411-412, 1981.
18. R. Schwarcz, J. P. Bruno, P. J. Muchowski, and H.-Q. Wu, "Kynurenines in the mammalian brain: when physiology meets pathology, " Nature Reviews Neuroscience, vol. 13, no. 7, pp. 465-477, 2012.
19. L. Z. Agudelo, T. Femenia, F. Orhan et al., "Skeletal muscle PGC-1 alpha 1modulates kynureninemetabolism and mediates resilience to stress-induced depression, " Cell, vol. 160, no. 1-2, pp. 351-351, 2015.
20. Y.-I. Jeong, S. W. Kim, I. D. Jung et al., "Curcumin suppresses the induction of indoleamine 2, 3-dioxygenase by blocking the Janus-activated kinase-protein kinase C-STAT1 signaling pathway in interferon-stimulated murine dendritic cells, " Journal of Biological Chemistry, vol. 284, no. 6, pp. 3700-3708, 2009.
21. M. C. Cuffy, A. M. Silverio, L. Qin et al., "Induction of indoleamine 2, 3-dioxygenase in vascular smooth muscle cells by interferon-contributes tomedial immunoprivilege, " Journal of Immunology, vol. 179, no. 8, pp. 5246-5254, 2007.
22. A. L. Mellor and D. H. Munn, "IDO expression by dendritic cells: Tolerance and tryptophan catabolism, " Nature Reviews Immunology, vol. 4, no. 10, pp. 762-774, 2004.
23. D. H. Munn, E. Shafizadeh, J. T. Attwood, I. Bondarev, A. Pashine, and A. L. Mellor, "Inhibition of T cell proliferation by macrophage tryptophan catabolism, " Journal of Experimental Medicine, vol. 189, no. 9, pp. 1363-1372, 1999.
24. G. K. Lee, H. J. Park, M. MacLeod, P. Chandler, D. H. Munn, and A. L. Mellor, "Tryptophan deprivation sensitizes activated T cells to apoptosis prior to cell division, " Immunology, vol. 107, no. 4, pp. 452-460, 2002.
25. P. Terness, T. M. Bauer, L. Röse et al., "Inhibition of allogeneic T cell proliferation by indoleamine 2, 3-dioxygenase-expressing dendritic cells: mediation of suppression by tryptophan metabolites, " Journal of Experimental Medicine, vol. 196, no. 4, pp. 447-457, 2002.
26. J. D. Mezrich, J. H. Fechner, X. Zhang, B. P. Johnson, W. J. Burlingham, and C. A. Bradfield, "Aninteraction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells, " Journal of Immunology, vol. 185, no. 6, pp. 3190-3198, 2010.
27. F. Fallarino, U. Grohmann, S. You et al., "The combined effects of tryptophan starvation and tryptophan catabolites downregulate T cell receptor-chain and induce a regulatory phenotype in naive T cells, " Journal of Immunology, vol. 176, no. 11, pp. 6752-6761, 2006.
28. A. L. Coln-González, P. D. Maldonado, and A. Santamara, "3-Hydroxykynurenine: An intriguing molecule exerting dual actions in the Central Nervous System, " NeuroToxicology, vol. 34, no. 1, pp. 189-204, 2013.
29. H. Mangge, K. L. Summers, A. Meinitzer et al., "Obesity-related dysregulation of the Tryptophan-Kynurenine metabolism: role of age and parameters of the metabolic syndrome, " Obesity, vol. 22, no. 1, pp. 195-201, 2014.
30. M. Pertovaara, A. Raitala, M. Juonala et al., "Indoleamine 2, 3-dioxygenase enzyme activity correlates with risk factors for atherosclerosis: The cardiovascular risk in young finns study, " Clinical and Experimental Immunology, vol. 148, no. 1, pp. 106-111, 2007.
31. P. Niinisalo, A. Raitala, M. Pertovaara et al., "Indoleamine 2, 3-dioxygenase activity associates with cardiovascular risk factors: The health 2000 study, " Scandinavian Journal of Clinical and Laboratory Investigation, vol. 68, no. 8, pp. 767-770, 2008.
32. P. Niinisalo, N. Oksala, M. Levula et al., "Activation of indoleamine 2, 3-dioxygenase-induced tryptophan degradation in advanced atherosclerotic plaques: Tampere Vascular Study, " Annals of Medicine, vol. 42, no. 1, pp. 55-63, 2010.
33. B. Wirleitner, V. Rudzite, G. Neurauter et al., "Immune activation and degradation of tryptophan in coronary heart disease, " European Journal of Clinical Investigation, vol. 33, no. 7, pp. 550-554, 2003.
34. G. Sulo, S. E. Vollset, O. Nygard et al., "Neopterin and kynurenine-tryptophan ratio as predictors of coronary events in older adults, the Hordaland Health Study, " International Journal of Cardiology, vol. 168, no. 2, pp. 1435-1440, 2013.
35. E. R. Pedersen, Ø. Midttun, P. M. Ueland et al., "Systemic markers of interferon-mediated immune activation and longterm prognosis in patients with stable coronary artery disease, " Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 31, no. 3, pp. 698-704, 2011.
36. A. Kato, Y. Suzuki, T. Suda et al., "Relationship between an increased serum kynurenine/tryptophan ratio and atherosclerotic parameters in hemodialysis patients, " Hemodialysis International, vol. 14, no. 4, pp. 418-424, 2010.
37. K. K. Ray, D. A. Morrow, M. S. Sabatine et al., "Long-term prognostic value of neopterin: A novel marker of monocyte activation in patients with acute coronary syndrome, " Circulation, vol. 115, no. 24, pp. 3071-3078, 2007.
38. R. Brouns, R. Verkerk, T. Aerts et al., "The role of tryptophan catabolism along the kynurenine pathway in acute ischemic stroke, " Neurochemical Research, vol. 35, no. 9, pp. 1315-1322, 2010.
39. K. Sas, H. Robotka, é. Rózsa et al., "Kynurenine diminishes the ischemia-induced histological and electrophysiological deficits in the rat hippocampus, " Neurobiology of Disease, vol. 32, no. 2, pp. 302-308, 2008.
40. D. Pawlak, T. Domaniewski, M. Mysliwiec, and K. Pawlak, "Inflammation and the prevalence of cardiovascular disease in patients with end-stage renal disease, " Atherosclerosis Supplements, vol. 11, no. 2, pp. 41-41, 2010.
41. T. Ishii, H. Iwahashi, R. Sugata, and R. Kido, "Formation of hydroxanthommatin-derived radical in the oxidation of 3-hydroxykynurenine, " Archives of Biochemistry and Biophysics, vol. 294, no. 2, pp. 616-622, 1992.
42. T. Morita, K. Saito, M. Takemura et al., "3-Hydroxyanthranilic acid, an L-tryptophan metabolite, induces apoptosis in monocyte-derived cells stimulated by interferon-, " Annals of Clinical Biochemistry, vol. 38, no. 3, pp. 242-251, 2001.
43. S.-M. Lee, Y.-S. Lee, J.-H. Choi et al., "Tryptophan metabolite 3-hydroxyanthranilic acid selectively induces activated T cell death via intracellular GSHdepletion, " Immunology Letters, vol. 132, no. 1-2, pp. 53-60, 2010.
44. T. Hayashi, J.-H. Mo, X. Gong et al., "3-Hydroxyanthranilic acid inhibits PDK1 activation and suppresses experimental asthma by inducing T cell apoptosis, " Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 47, pp. 18619-18624, 2007.
45. M. Y. Chang, C. Smith, J. B. DuHadaway et al., "Cardiac and gastrointestinal liabilities caused by deficiency in the immune modulatory enzyme indoleamine 2, 3-dioxygenase, " Cancer Biology andTherapy, vol. 12, no. 12, pp. 1050-1058, 2011.
46. L. Zhang, O. Ovchinnikova, A. Jönsson et al., "The tryptophan metabolite 3-hydroxyanthranilic acid lowers plasma lipids and decreases atherosclerosis in hypercholesterolaemic mice, " European Heart Journal, vol. 33, no. 16, pp. 2025-2034, 2012.